Elizaria®

INN: Eculizumab

A humanized monoclonal antibody that binds to the human complement protein C5 and inhibits the activation of complement-mediated cytolysis.

Elizaria® inhibits the activation of the terminal complement complex in humans, restores the regulation of complement activity in the blood.

Elizaria® prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH), as well as excessive activation of the terminal complement complex in patients with atypical hemolytic uremic syndrome (aHUS).

Eculizumab treatment in patients leads to a significant decrease in hemolysis, frequency of thrombosis, dependence on blood transfusion in patients with paroxysmal nocturnal hemoglobinuria, and also significantly improves renal function in patients with atypical hemolytic uremic syndrome.

Indications for use:

  • Paroxysmal nocturnal hemoglobinuria (PNH)
  • Atypical hemolytic uremic syndrome (aHUS)

GENERIUM is the only company in the world that has developed and manufactured a biosimilar of Eculizumab.